Klyne
2 employees on LinkedIn Β· 2 known investors
Klyne develops binding affinity models for molecular prediction and offers a low-cost virtual screening service aimed at hit discovery and hit-to-lead optimization projects in drug discovery labs. It targets companies working on early-stage pharmaceutical research with limited budgets.
Investors Β· 2
Frequently asked questions
- What does Klyne do?
- Klyne develops binding affinity models for molecular prediction and offers a low-cost virtual screening service aimed at hit discovery and hit-to-lead optimization projects in drug discovery labs. It targets companies working on early-stage pharmaceutical research with limited budgets.
- Who are Klyne's investors?
- Klyne's investors include Fred Ehrsam, Fifty Years.